Ex Vivo Gene Therapy of Familial Hypercholesterolemia. Howard Hughes Medical Institute, University of Michigan

Human Gene Therapy

Volumn 3, Issue 2, 1992, Pages 179-222

  Wilson, James M ^a   Grossman, Mariann ^b   Raper, Steven E ^c   Baker, James R ^d   Newton, Roger S ^e   Thoene, Jess G ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Human Applications Laboratory ^*  (United States)

^c Surgery   (United States)

^d Internal Medicine   (United States)

^e Pharmacology ^*  (United States)

^f Section of Biochemical Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

ADOLESCENT; ADULT; ANIMAL; ARTICLE; CHILD; CLINICAL PROTOCOL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE THERAPY; GENETICS; HUMAN; INFANT; LIVER; MALE; PRESCHOOL CHILD; TISSUE TRANSPLANTATION;

ADOLESCENT; ADULT; ANIMAL; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; GENE THERAPY; HUMAN; HYPERCHOLESTEROLEMIA, FAMILIAL; INFANT; LIVER; MALE; RECEPTORS, LDL; TISSUE TRANSPLANTATION;

EID: 0026842933     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.1992.3.2-179     Document Type: Article

References (123)

1. Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, Apr 4 1986;232(4746):34–47.
2. Goldstein JL and Brown MS. Familial hypercholesterolemia. Lipoprotein and Lipid Metabolism Disorders. Metabolic Basis of Inherited Disease II 1989;1:1215–1250.
3. Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. Arteriosclerosis, Jan-Feb 1989;9(1 Suppl):I158–63.
4. Thompson GR, Barbir M, Okabayashi K, Trayner I and Larkin S. Plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, Jan-Feb 1989;9(1 Suppl):I152–57.
5. Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW Jr, Hardesty RL, Griffity BP, Iwatsuki S, Zitelli BJ, Gartner JC Jr, Malatack JJ, and et al. Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet, Jun 23 1984; 1(8391): 1382–1383.
6. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE and Brown MS. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med, Dec 27 1984; 311(26):1658–1664.
7. Shaw BW Jr., Bahnson HT, Hardesty RL, Griffity BP and Starzl TE. Combined transplantation of the heart and liver. Ann Surg, Dec 1985;202(6):667–672.
8. Hoeg JM, Starzl TE and Brewer HB Jr. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. Am J Cardio, Mar 1 1987;59(6):705–707.
9. Valdivielso P, Escolar JL, Cuervas-Mons V, Pulpon LA, Chaparro MA and Gonzalez-Santos P. Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Ann Intern Med, Feb 1988; 108(2):204–206.
10. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL rabbit). Atherosclerosis, Jun 1980;36(2): 261–8.
11. Goldstein JL, Kita T and Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med, Aug 4 1983; 309(5):288–296.
12. Yamamoto T, Bishop RW, Brown MS, Goldstein JL and Russell DW. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science, Jun 6 1986;232(4755): 1230–37.
13. Havel RJ, Yamada N and Shames DM. Watanabe heritable hyperlipidemic rabbit. Animal model for familial hypercholesterolemia. Arteriosclerosis, Jan-Feb 1989;9(1 Suppl):I33–38.
14. Wilson JM, Johnston DE, Jefferson DM and Mulligan RC. Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA, Jun 1988;85(12):4421–4425.
15. Wilson JM and Chowdhury JR. Prospects for gene therapy of familial hypercholesterolemia. Mol Biol Med, Jun 1990;7(3): 223–32.
16. Wilson JM, Chowdhury NR, Grossman M, Wajsman R, Epstein A, Mulligan RC and Chowdhury JR. Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. Proc Natl Acad Sci USA, Nov 1987;87(21):8437–8441.
17. Wilson JM, Chowdhury NR, Grossman M, Gupta SJ, Jeffers J, Huang TJ and Chowdhury JR. Transplantation of allogeneic hepatocytes into LDL receptor deficient rabbits leads to transient improvement in hypercholesterolemia. Clin Biotech, Spring 1991;3:21–26.
18. Chowdhury JR, Grossman M, Gupta SJ, Chowdhury NR, Baker JR Jr and Wilson JM. Long term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR deficient rabbits. Science, 1991;254:1802–1805.
19. Grossman M, Raper S and Wilson JM. Towards liver-directed gene therapy: retrovirus mediated gene transfer into human hepatocytes. Som Cell Mol Gen 1991;17:601–607.
20. Friedmann T. Progress toward human gene therapy. Science, Jun 16 1989;244(4910): 1275–81.
21. Wilson JM, Jefferson DM, Chowdhury JR, Novikoff PM, Johnston DE and Mulligan RC. Retrovirus-mediated transduction of adult hepatocytes. Proc Natl Acad Sci USA, May 1988; 85(9):3014–3018.
22. Williams DA, Lemischka IR, Nathan DG and Mulligan RC. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature, Aug 9–15 1984;310(5977): 476–80.
23. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P. Stratford-Perricaudet LD, Perricaudet M, Jalat S, Pavirani A, Lecocq JP and Crystal RG. Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science, Apr 19 1991;252:431–434.
24. Culver K, Cornetta K, Morgan R, Morecki S, Aebersold P, Kasid A, Lotze M, Rosenberg SA, Anderson WF and Blaese R.M., Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA, Apr 15 1991;88(8):3155–3159.
25. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD and Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science, Jun 16 1989; 244(4910): 1344–46.
26. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Felgner PL. Direct gene transfer into mouse muscle in vivo. Science, Mar 23 1990:247(4949 Part 1): 1465–68.
27. Lin H, Parmacek HS, Morle G, Bolling S and Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation, Dec 1990;82(6):2217–2221.
28. Axelrod JH, Read MS, Brinkhous KM and Verma IM. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci USA, July 1990; 87(13):5173–5177.
29. Morgan JR, Barrandon Y, Green H and Mulligan RC. Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science, Sep 18 1987;237(4821): 1476–79.
30. Palella TD, Hidaka Y, Silverman LJ, Levine M, Glorioso J and Kelley WN. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene, Aug 1 1989;80(1):137–144.
31. Cepko CL, Roberts BE and Mulligan RC. Construction and applications of a highly transmissable murine retrovirus shuttle vector. Cell, Jul 1984;37(3): 1053–62.
32. Samulski RJ, Chang LS and Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol, Sep 1989;63(9):3822–3828.
33. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA, Nov 1987;84(21):7413–7417.
34. Nicolau C and Legrand A, Grosse E. Liposomes as carriers for in vivo gene transfer and expression. Methods Enzymol, 1987; 149:157–176.
35. Wu GY and Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system [published erratum appears in J Biol Chem, Jan 5, 1988;263(1):588]
36. J Biol Chem, Apr 5 1987;262(10):4429–4432.
37. Russell DW, Esser V and Hobbs HH. Molecular basis of familial hypercholesterolemia, Arteriosclerosis, Jan-Feb 1989;9(1 Suppl): 18–13.
38. Lodstein JL, Dana SE and Brown MS. Esterification of low density lipoprotein cholesterol in human fibroblasts and its absence in homozygous familial hypercholesterolemia. Proc Natl Acad Sci USA, Nov 1974;71(11):4288–4292.
39. Glickman RM and Sabesin SM. Lipoprotein metabolism. In The Liver: Biology and Pathophysiology (Aria IM, Jakoby WB, Popper H, Schachter D and Shafritz DA, eds), 2nd edit., 1988, pp. 331–354, Raven Press Ltd, New York.
40. Turley SD and Dietschy JM. The metabolism and excretion of cholesterol by the liver. In The Liver: Biology and Pathophysiology (Aria IM, Jakoby WB, Popper H, Schachter D and Shafritz DA, eds), 2nd edit., 1988, pp. 617–641, Raven Press Ltd, New York.
41. Robins SJ, Fasulo JM, Collins MA and Patton GM. Evidence for separate pathways of transport of newly synthesized and preformed cholesterol into bile. J Biol Chem, Jun 10 1985; 260(11):6511–6513.
42. Sprecher DL, Hoeg JM, Schaefer EJ, Zech LA, Gregg RE, Lakatos E and Brewer HB, Jr. The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. Metabolism, Mar 1985;34(3): 294–99.
43. Goldstein JL and Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am, Mar 1982;66(2):335–362.
44. Sprecher DL, Schaefer EJ, Kent KM, Gregg RE, Zech LA, Hoeg JM, McManus B, Roberts WC and Brewer HB, Jr. Cardiovascular features of homozygous familial hpyercholesterolemia analysis of 16 patients. Am J Cardiol, July 1 1984;54(1);20–30.
45. Haitas B, Baker SG, Meyer TE, Joffe BI and Seftel HC. Natural history and cardiac manifestations of homozygous familial hypercholesterolemia. Q J Med, Jul 1990;76(279):731–740.
46. Khachadurian AK and Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. NutrMetab, 1973;15(1):132–140.
47. Mabuchi H, Tatami R, Haba T, Ueda K, Ueda R, Kametani T, Itoh S, Koizumi J, Oota M, Miyamoto S, Takeda R and Takeshita H. Homozygous familial hypercholesterolemia in Japan. Am J Med, Aug 1978;65(2):290–297.
48. Mabuchi H, Koizumi H, Shimizu M and Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation, Feb 1989;79(2):225–232.
49. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, and Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis, Mar-Apr 1989; 9(2):211–216.
50. Lehrman MA, Schneider WJ, Brown MS, David CG, Elhammer A, Russell DW and Goldstein JL. The Lebanese allele at the low density lipoprotein receptor that is retained in endoplasmic reticulum. J Biol Chem, Jan 5 1987;262(1):401–410.
51. Leitersdorf E, Tobin EJ, Davignon J and Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest, Apr 1990;85(4): 1014–23.
52. Goldstein JL and Brown MS. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res, Dec 15 1984; 25(13):1450–1461.
53. Sudhof TC, Russell DW, Brown MS and Goldstein JL. 42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter. Cell, Mar 27 1987;48(6): 1061–69.
54. Miyanohara A, Sharkey MF, Witztum JL, Steinberg D and Freidmann T. Efficient expression of retroviral vector-transduced human low density lipoprotein (LDL) receptor-deficient rabbit fibroblasts in vitro. Proc Natl Acad Sci USA, Sep 1988; 85(17):6538–6542.
55. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL and Russell DW. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell, Nov 1984;39(1):27–38.
56. Davis CG, van Driel IR, Russell DW, Brown MS and Goldstein JL. The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem, Mar 25 1987;262(9):4075–4082.
57. Hofmann SL, Russell DW, Brown MS, Goldstein JL and Hammer RE. Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. Science, Mar 11, 1988;239(4845): 1277–81.
58. Yokode M, Hammer RE, Ishibashi S, Brown MS and Goldstein JL. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science, Nov 30 1990; 250(4985): 1273–75.
59. Khachadurian AK. Cholestyramine therapy in patients homozygous for familial hypercholesterolemia (familial hypercholesterolemic xanthomatosis). J Atheroscler Res, Jan-Feb 1968; 8(1):177–188.
60. Levy RI, Fredrickson DS, Stone NJ, Bilheimer DW, Brown WV, Glueck CJ, Gotto AM, Herbert PN, Kwiterovich PO, Langer T, LaTosa J, Lux SE, Rider AK, Shulman RS and Sloan HR. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. Ann Intern Med, Jul 1973;79(1):51–58.
61. Yamamoto A, Yamamura T, Yokoyama S, Sudo H and Matsuzawa Y. Combined drug therapy-cholstyramine and compactin-for familial hypercholesterolemia. Int J Clin Pharmacol Ther Toxicol, Sep 1984;22(9):493–497.
62. Malloy MJ, Kane JP, Kunitake ST and Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med, Nov 1987;107(5):616–623.
63. Uauy R, Vega GL, Grundy SM and Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr, Aug 1988;113(2):387–392.
64. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis, Jan-Feb 1989;9(1 Suppl):I145–51.
65. Starzl TE, Putnam CW, Chase HP and Porter KA. Portacaval shunt in hyperlipoproteinaemia. Lancet, Oct 27 1973; 2(835):940–944.
66. Starzl TE, Chase HP, Ahrens EH Jr, McNamara DJ, Bilheimer DW, Schaefer EJ, Rey J, Porter KA, Stein E, Francavilla A and Benson LN. Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg, Sep 1983;198(3):273–283.
67. Thompson GR, Lowenthal R and Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet, May 31 1975;1(7918):1208–1211.
68. Apstein CS, Zilversmit DB, Lees RS and George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis, Oct 1978; 31(2):105–115.
69. King ME, Breslow JL and Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med, Jun 1980;302(26): 1457–9.
70. Myant NB. Regression of coronary atherosclerosis in man. Adv Exp Med Biol, 1984;168:139–152.
71. Yokoyama S, Hayashi R, Satani M and Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, Nov-Dec 1985; 5(6):613–622.
72. Postiglione A and Thompson GR. Experience with plasma-exchange in homozygous familial hypercholesterolemia. Prog Clin Biol Res, 1985;188:213–220.
73. Thompson GR, Miller JP and Breslow JL. Improved survival of patients with homozygous familial hypercholesterolemia treated with plasma exchange. Br Med J [Clin Res], Dec 14, 1985; 291(6510):1671–1673.
74. Keller C, Schmitz H, Theisen K and Zollner N. Regression of valvular aortic stenosis due to homozygous familial hypercholesterolemia following plasmapheresis. Klin Wochenschr, Apr 1 1986;64(7):338–341.
75. Stein EA, Adolph R, Rice V, Glueck CJ and Spitz HB. Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. Clin Cardiol, Mar 1986;9(3):115–119.
76. Lupien PJ, Moorjani S, Gagne C, Brun LD, Lou M and Dagenais G. Long term treatment of two familial hypercholesterolemic heterozygote patients with batch affinity chromatography (BAC). Artery, 1982;10(4):286–300.
77. Stoffel W and Demant T. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Natl Acad Sci USA, Jan 1981;78(1):611–615.
78. Yodoyama S, Hayashi R, Satani M and Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, Nov-Dec 1985; 5(6):613–622.
79. Gwynn JT. Probucol, high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardio, Jul 25 1988; 62(3):48B-51B.
80. Baker SG, Joffe BI, Mendelsohn D and Seftel HC. Treatment of homozygous familial hypercholesterolemia with probucol. S Afr Med J, Jul 3 1982;62(1):7–11.
81. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Oshima A, Yoshida H and Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA, Aug 1987;84(16):5928–5931.
82. Leonard JV, Clarke M, McCartney FJ and Slack. Progression of atheroma in homozygous familial hypercholesterolemia during regular plasma exchange [letter]. Lancet, Oct 10 1981; 2(850):811.
83. Deckelbaum RJ, Lees RS, Small DM, Hedberg SE, Grundy SM. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia. N Engl J Med, Mar 3 1977;296(9):465–470.
84. Schneider WJ, Brown MS, and Goldstein JL. Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia. Mol Biol Med, Oct 1983;1(3):353–367.
85. Tanzawa K, Shimada Y, Kuroda M, Tsujita Y, Arai M and Watanabe H. WHHL rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS, Aug 25 1980;118(1):81–84.
86. Pittman RC, Carew TE, Attie AD, Witzman JL, Watanabe Y, and Steinberg D. Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. J Biol Chem, Jul 1982; 257(14):7994–8000.
87. Kita T, Brown MS, Watanabe Y and Goldstein JL. Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA, Apr 1981;78(4):2268–2272.
88. Bilheimer DW, Watanabe Y and Kita T. Impaired receptor-mediated catabolism of low density lipoprotein in the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA, May 1982;79(10):3305–3309.
89. Kita T, Brown MS, Bilheimer DW and Goldstein JL. Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoproteins in WHHL rabbits. Proc Natl Acad Sci USA, Sep 1979;79(18): 5693–7.
90. Wiederkehr JC, Kondos GT and Pollak R. Hepatocyte transplantation for the low-density lipoprotein receptor-deficient state. A study in the Watanabe rabbit, Transplantation, Sep 1990; 50(3):466–471.
91. Danos O and Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA, Sep 1988;85(17):6460–6464.
92. Price J, Turner D and Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA, Jan 1987;84(1): 156–60.
93. Godbout R, Ingram RS and Tilghman SM. Fine-structure mapping of the three mouse alpha-fetoprotein gene enhancers. Mol Cell Biol, Mar 1988;8(3): 1169–78.
94. Wilson JM, Jefferson DM, Chowdhury JR, Novikoff PM, Johnston DE and Mulligan RC. Retrovirus-mediated transduction of adult hepatocytes. Proc Natl Acad Sci USA, May 1988; 85(9):3014–3018.
95. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF and Gilboa E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA, May 1986,83(10): 3194–8.
96. Goldman L. Cardiac risks and complications of noncardiac surgery. Ann Intern Med, Apr 1983;98(4):504–513.
97. Weitz HH and Goldman L. Noncardiac surgery in the patient with heart disease. Med Clin North Am, May 1987;71(3):413–432.
98. Lim JS, Proudfit WL and Sones FM Jr. Left main coronary arterial obstruction: Long-term follow-up of 141 nonsurgical cases. Am J Cardiol, Aug 1975;36(2):131–135.
99. Bruschke AV, Proudfit WL and Sones FM Jr. Progress study of 590 consecutive nonsurgical cases of coronary disease followed by 5–9 years. I. Arterographic correlations. Circulation, Jun 1973;47(6): 1147–53.
100. Kramer JR, Kitazume H, Proudfit WL, Matsuda Y, Williams GW and Sones FM Jr. Progression and regression of coronary atherosclerosis:relation to risk factors. Am Heart J, Jan 1983; 105(1):134–144.
101. Killip T, Passamani E and Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary bypass surgery. Eight years follow-up and survival in patients with reduced ejection fraction. Circulation, Dec 1985;72(6 Part 2):V102-V109.
102. Glueck CJ. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Am J Cardiol, May 1986;57(14):35G-41G.
103. Leffert HL, Koch KS, Moran T and Williams M. Liver cells. Methods Enzymol, 1979;58:536–544.
104. Enat R, Jefferson DM, Ruiz-Opazo N, Gatmaitan Z, Leinwald LA and Reid LM. Hepatocyte proliferation in vitro: its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix. Proc Natl Acad Sci USA, 1984;81:1411–1415.
105. Korman AJ, Frantz JD, Strominger JL and Mulligan RC. Expression of human class II major histocompatibility complex antigens using retrovirus vectors. Proc Natl Acad Sci USA, Apr 1987; 84(8):2150–2154.
106. Van Beveren F, Coffin J and Hughes S. In RNA Tumor Viruses (Weiss R, Teich N, Varmus H and Coffin J, eds.) 2nd edit, 1985, Cold Spring Harbor Lab., Cold Spring Harbor, NY; pp. 766–783.
107. Kost TA, Theodorakis N and Hughes SH. The nucleotide sequence of the chick cytoplasmic beta-actin gene. Nucleic Acids Res, Dec 1983;11(23):8287–8301.
108. Seed B and Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci USA, May 1987;84(10):3365–3369.
109. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B and Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell, Jun 1985;41(2):521–530.
110. Memsic L, Busuttil RW and Traverso LW. Bleeding esophageal varices and portal vein thrombosis after pancreatic mixed-cell autotransplantation. Surgery, 1984;95:238–242.
111. Lawrence TS, Dworzanin LN, Walker-Andrews SC, Andrews JC, TenHaken RK, Wollner IS, Lichter AS and Ensminger WD. Treatment of cancers involving the liver and porta hepatitis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiation Oncology, 1991;29:555–561.
112. Mullen Y, Clare-Salzler M, Stein E and Clark W. Islet transplantation for the cure of diabetes. Pancreas, 1989;4(1): 123–135.
113. Sterneck M, Ring E, Gordon R, LaBerge J, Roberts J, Asher N and Lake J. Intrahepatic portacaval shunt (IPCS): A bridge to liver transplantation in patients with refractory variceal bleeding. Gastroenterology, 1991;100:A193.
114. Chang PL, Capone JP and Brown GM. Autologous fibroblast implantation. Feasibility and potential problems in gene replacement therapy. Mol Biol Med, Dec 1990;7(6):461–470.
115. van Driel IR, Goldstein JL, Sudhof TC and Brown MS. First cysteine-rich repeat in ligand-binding domain of low density lipoprotein receptor binds Ca2+ and monoclonal antibodies, but not lipoproteins. J Biol Chem, Dec 1987;262(36): 17443–17449.
116. van Driel IR, Brown MS and Goldstein JL. Stoichiometric binding of low density lipoprotein (LDL) and monoclonal antibodies to LDL receptors in a solid phase assay. J Biol Chem, Jun 1989;264(16):9533–9538.
117. Huettinger M, Schneider WJ, Ho YK, Goldstein JL and Brown MS. Use of monoclonal anti-receptor antibodies to probe the expression of the low density lipoprotein receptor in tissues of normal and Watanabe heritable hyperlipidemic rabbits. J Clin Invest, Sep 1984;74(3): 1017–24.
118. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J, Nov 1985; 110(5): 1100–7.
119. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S and Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, Nov 1986;256(20):2835–2838.
120. Abbott RD, Wilson PW, Kannel WB and Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis, May-Jun 1988;8(3):207-ll.
121. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol, Jul 1988;4 Suppl A:5A-10A.
122. Cornetta K, Morgan RA and Anderson WF. Safety issued related to retroviral-mediated gene transfer in humans. Hum Gene Ther, Spring 1991;2(1):5–14.
123. Cornetta K, Moen RC, Culver K, Morgan RA, McLachlin JR, Sturm S, Selegue J, London W, Blaese RM and Anderson WF. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther, Spring 1990; 1(1): 15–30.